Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for Liver Fibrosis in NAFLD
NCT03357380Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2017
- Primary completion
- Mar 2020
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in non-alcoholic fatty liver disease (NAFLD) comparing Semaglutide with Placebo (2 arms). Primary endpoint: Change in liver stiffness assessed by magnetic resonance elastography (MRE) at 48 weeks. Started Nov 2017; status: completed.
02
Drugs
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT03357380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03357380.